ASP Isotopes (NASDAQ:ASPI) Director Robert John Andrew Ryan Acquires 15,000 Shares of Stock

ASP Isotopes Inc. (NASDAQ:ASPI) Director John Ryan acquired 15,000 shares of the business’s stock in a transaction that occurred on Wednesday, September 30th. The shares were bought at an average price of $2.68 per share, for a total transaction of $40,200.00. Following the completion of the purchase, the director owned 675,222 shares of the company’s stock, valued at approximately $1,809,594.96. This represents a 2.27% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Robert John Andrew Ryan also recently made the following trade(s):

• On Monday, September 28th, John Ryan acquired 8,000 shares of ASP Isotopes stock. The stock was bought at an average cost of $2.70 per share, with a total value of $21,600.00.

ASP Isotopes Price Performance

ASPI traded up $0.05 on Thursday, reaching $2.70. The company had a trading volume of 5,479,989 shares, compared to its average volume of 4,790,329. The company has a market capitalization of $413.94 million, a P/E ratio of -2.05 and a beta of 3.59. The company has a current ratio of 3.87, a quick ratio of 3.85 and a debt-to-equity ratio of 0.76. The company has a fifty day moving average of $3.75 and a 200-day moving average of $4.91. ASP Isotopes Inc. has a one year low of $2.51 and a one year high of $14.49.

ASP Isotopes (NASDAQ:ASPI) last released its quarterly earnings results on Friday, August 14th. The company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.11). The company had revenue of $5.12 million for the quarter, compared to the consensus estimate of $4.47 million. ASP Isotopes had a negative return on equity of 64.99% and a negative net margin of 427.98%.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on ASPI. Wall Street Zen raised ASP Isotopes from a “strong sell” rating to a “sell” rating in a report on Saturday, August 22nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ASP Isotopes in a research note on Monday, September 21st. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, ASP Isotopes currently has a consensus rating of “Hold” and a consensus target price of $13.00.

Institutional Investors Weigh In On ASP Isotopes

Institutional investors and hedge funds have recently bought and sold shares of the business. WINTON GROUP Ltd bought a new position in shares of ASP Isotopes during the 2nd quarter valued at about $588,000. Integrated Wealth Concepts LLC acquired a new stake in ASP Isotopes during the second quarter valued at approximately $176,000. Squarepoint Ops LLC lifted its stake in ASP Isotopes by 75.6% during the second quarter. Squarepoint Ops LLC now owns 123,951 shares of the company’s stock valued at $771,000 after purchasing an additional 53,354 shares during the last quarter. Amundi bought a new stake in ASP Isotopes during the second quarter worth approximately $107,000. Finally, AXQ Capital LP bought a new stake in ASP Isotopes during the second quarter worth approximately $80,000. 16.80% of the stock is owned by institutional investors and hedge funds.

ASP Isotopes Company Profile

ASP Isotopes Inc (NASDAQ: ASPI) is a development-stage company focused on isotope enrichment and related technologies. The company is developing an isotope-separation platform known as the Aerodynamic Separation Process, which is intended to enrich selected chemical elements and isotopes for use in several specialized markets.

ASP Isotopes has identified applications in the nuclear energy, medical, semiconductor, and quantum-computing industries. Its development programs have included uranium enrichment as well as the production of specialty isotopes such as carbon-14, molybdenum-100, and silicon-28.